Mengniu emerge as a pioneer in developing nutritional ingredients, particularly through groundbreaking advancements in HMO technology
In August 2024, Synaura Biotechnology a subsidiary of China Mengniu Dairy Company Limited, received GRAS certification from the U.S. Food and Drug Administration (FDA) for its 2′-FL (2′-Fucosyllactose), making it the first and only human milk oligosaccharides (HMOs) company from China to receive approval.
HMOs are the third largest solid component in human breast milk, following fat and lactose, and contribute significantly to infant health by enhancing gut health, supporting the immune system, and aiding cognitive development. Despite their immense potential when used in nutritional products, little progress has been made in the research development and industrialization of HMO raw materials by Chinese companies. The most recent technological breakthroughs were all achieved by multinational companies.
Recent years have witnessed Mengniu emerge as a pioneer in developing nutritional ingredients, particularly through groundbreaking advancements in HMO technology. As one of the leading biosynthesis companies in China and the first domestic company engaged in HMO research and development, Synaura’s flagship HMOs have garnered recognition from several regulatory bodies both domestically and internationally. In June 2023, Synaura became the first Chinese company to obtain Self-Affirmed GRAS (Generally Recognized as Safe) certification in the U.S. In October 2023, Synaura became the only domestic HMO supplier to receive approval from China’s National Health Commission (NHC) for its 2′-FL (2′-Fucosyllactose). Recognition from multiple regulatory bodies underscores the product’s safety, efficacy, and purity at an international level while unlocking promising market opportunities for broader applications.
